Cytomegalovirus (CMV) is killed by antiviral medications inside the body, by your immune system’s T cells during active infection, and by surprisingly simple measures like soap and water on surfaces and skin. Because CMV establishes a lifelong latent infection once you contract it, “killing” the virus means different things depending on context: stopping it from replicating during an active flare, preventing it from spreading on surfaces, or keeping it suppressed so it never reactivates.
How Antiviral Medications Stop CMV
The primary drugs used against active CMV infection all target the same weak point: the virus’s DNA-copying machinery. CMV needs its own specialized enzyme to replicate its genetic material, and antiviral medications jam that enzyme far more effectively than they interfere with your own cells’ DNA machinery. That selectivity is what makes them useful as treatments rather than poisons.
Ganciclovir (and its oral form, valganciclovir) is the most commonly used first-line treatment. Once inside a CMV-infected cell, it gets activated by a viral protein, then blocks the virus’s ability to copy its DNA. Because only infected cells activate the drug, healthy cells are largely spared. For CMV eye infections, the oral version is typically taken twice daily for 21 days, then once daily as ongoing maintenance. Transplant patients often take it preventively for 100 to 200 days after surgery, depending on the organ.
When the first-line drugs don’t work or the virus develops resistance, doctors turn to alternatives. Foscarnet works differently: instead of mimicking a DNA building block, it physically blocks a different part of the replication enzyme. Cidofovir takes yet another approach but still targets the same core copying process. These backup options come with heavier side effects. Foscarnet causes kidney damage in 20% to 66% of patients and can throw off calcium, magnesium, and potassium levels. It also frequently causes nausea severe enough that some patients can’t tolerate it.
For CMV strains that resist all three of these older drugs, maribavir offers a newer option. It has proven active against CMV strains resistant to ganciclovir, foscarnet, and cidofovir, and has been used in transplant recipients whose infections failed to respond to at least two weeks of standard treatment. A separate drug, letermovir, is approved specifically to prevent CMV reactivation in bone marrow transplant recipients, though its role in treating active infections is still limited.
Your Immune System Is the Main Defense
For most healthy people, the immune system handles CMV without any medication at all. Two types of T cells do the heavy lifting. CD8+ T cells (sometimes called “killer” T cells) are the rapid responders. They identify cells actively producing new virus particles and destroy them, terminating replication in the short term. CD4+ T cells play the longer game, maintaining surveillance that keeps the virus from reactivating from its dormant state over months and years.
This is why CMV is primarily dangerous for people with weakened immune systems: transplant recipients on immunosuppressive drugs, people with advanced HIV, and newborns whose immune systems haven’t fully developed. In these groups, the T-cell response can’t keep up, and the virus replicates unchecked. Healthy adults who contract CMV often never realize it because their immune system suppresses it so effectively. The virus remains in the body permanently, hiding in certain white blood cells in a dormant state, but a functioning immune system keeps it from causing harm.
What Kills CMV on Surfaces
Outside the body, CMV is relatively fragile compared to some other viruses, but it can survive long enough on everyday objects to spread. On metal, it dies within about 2 hours. Glass and plastic surfaces keep it viable for up to 3 hours. Rubber, cloth, and even food items like crackers can harbor infectious virus for up to 6 hours. Some data suggest survival on dry surfaces can occasionally extend to 7 days under certain conditions, though most common household materials see the virus die off well before that.
Heat kills CMV efficiently. Temperatures above 60°C (140°F) for just 5 seconds are enough to inactivate the virus. This is why short-term pasteurization at 62°C for 5 seconds has been studied as a way to make breast milk safe for premature infants, who are especially vulnerable to CMV infection.
Soap and Water Work Remarkably Well
One of the most practical findings for everyday life: plain soap and water completely eliminates live CMV from hands. In a controlled study testing various hand-cleaning methods on people whose hands were contaminated with CMV, every single approach worked. Water alone (rinsing for 15 seconds), plain soap, antibacterial soap, and alcohol-based hand sanitizer all reduced recoverable live virus to zero.
There’s an interesting distinction, though. Soap and water physically removed the viral material from skin, washing away both the live virus and its genetic remnants. Hand sanitizer killed the virus just as effectively, but left the viral DNA behind on the skin surface. In practical terms, both approaches eliminate the infection risk, but soap and water does the more thorough job of clearing viral material entirely. For anyone concerned about CMV transmission, particularly parents of young children or pregnant women around toddlers in daycare, consistent handwashing after contact with saliva, urine, or tears is the single most effective prevention measure.
Why CMV Can Never Be Fully Eliminated
Every treatment and immune response described above targets CMV while it’s actively replicating. None of them can reach the virus in its latent state, when its genetic material sits quietly inside certain cells without producing new virus particles. This is why CMV infection is permanent: once you have it, no drug or immune response can root out every last copy of the dormant virus.
An mRNA-based vaccine (mRNA-1647) is currently in a Phase 3 clinical trial with over 7,400 participants, targeting women aged 16 to 40 who are most likely to encounter CMV through contact with young children. The trial completed enrollment in October 2023. If successful, it would be the first vaccine capable of preventing CMV infection before it ever takes hold, sidestepping the problem of latency entirely.